Cancer: 2
Life Sciences
Information and Communication
Nanotechnology / Materials
Manufacturing Technology
Human and Social Sciences
Energy
Environment
Tourism / Community development
Arctic Research
Social Infrastructure
Open Facilities
View All
View Detail-
Hyperpolarized 13C MRI for Genetic Mutation Imaging
Non-invasive visualization of genetic mutations in tumors by metabolic MRI
The outcome of cancer treatment largely depends on the type of genetic mutation that the cancer cells carry. Using the characteristic metabolic changes brought about by genetic mutations as an indicator, we are developing a molecular imaging technique to identify mutated genes non-invasively using the latest metabolic MRI.
Research
Hyperpolarized 13C nuclear magnetic resonance imaging (MRI) is a state-of-the-art technique for real-time visualization of metabolic reactions in vivo by temporarily amplifying the MRI signal of any compound labeled with 13C tens of thousands of times. It is expected to be a dream molecular imaging technology that can acquire signals from deep inside the body, which is difficult with optical imaging without radiation exposure like PET/CT.
Cells become cancerous through the accumulation of genetic mutations, and the type of mutation greatly influences the response to cancer therapy. Many cancer-causing mutations are associated with characteristic metabolic changes. Hyperpolarized 13C MRI can be used to non-invasively identify mutated genes in tumors by looking at specific metabolic changes.Shingo Matsumoto Professor -
Tumor Angiogenesis Inhibitor Screening System
A cell-based screening assay system for the development of tumor angiogenesis inhibitors
We aim to realize cell-based screening using tumor vascular endothelial cells, and contribute to the development of next-generation angiogenesis inhibitor therapies by overcoming problems of existing angiogenesis inhibitors (side effects, lack of companion diagnostics).
Research
Thanks to the development of molecular targeted therapies, antiangiogenic agents are now widely used. However, there are problems such as the lack of companion diagnostics to predict therapeutic effects and side effects due to injury to normal blood vessels.
We have successfully isolated and cultured human tumor vascular endothelial cells and have identified specific markers that they express. Tumor vascular endothelial cells expressing these markers are valuable materials for cell-based screening of novel drugs and compounds, and help us identify new therapeutic targets and drugs that cannot be discovered by studies using conventional tumor cell lines or clinical tumor tissue fragments. Markers expressed by these tumor vascular endothelial cells can also be used as companion diagnostics. This will contribute to the realization of personalized treatment by selecting the target cases as well as the timing and duration of administration with angiogenesis inhibitors.Kyoko Hida Professor
